Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

Crystalys Therapeutics raises $130M Series B — Jul 22, 2026Crystalys Therapeutics has raised a $130 million Series B led by Frazier Life Sciences with participation from multiple investors to fund late-stage global trials and commercialization plans for dotinurad, its URAT1 inhibitor for gout. The financing backs the RUBY, TOPAZ, and AMETHYST studies and aims to accelerate regulatory milestones and commercial readiness across the U.S. and Europe as the company positions dotinurad as a best-in-class option between first-line therapies and last-line treatments.